Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

研究方向

Apoptosis 相关产品(2721)

  • GC72061 structure
    GC72061β-Phellandrene
    CAS: 555-10-2
    纯度: >95.00%

    β-Phellandrene是从岩骨中获得的。

  • GC72103 structure
    GC72103Kp7-6
    CAS: 629628-53-1
    纯度: >98.00%

    Kp7-6是一种Fas模拟肽,是一种Fas/FasL拮抗剂。

  • GC72146 structure
    GC72146WP9QY TFA
    纯度: >99.00%

    WP9QY TFATNF-a拮抗剂是一种生物活性肽。

  • GC72147 structure
    GC72147Mca-YVADAP-Lys(Dnp)-OH TFA
    纯度: >98.00%

    Mca-YVADAP-Lys(Dnp)-OH TFA是caspase-1和血管紧张素转换酶ACE2的荧光底物。

  • GC72183 structure
    GC72183[D-Leu-4]-OB3
    CAS: 289056-32-2
    纯度: >99.00%

    [D-Leu-4]-OB3抑制促炎、增殖和转移基因的表达以及pd - l1的表达。

  • GC72186 structure
    GC72186WLSEAGPVVTVRALRGTGSW
    CAS: 771479-86-8
    纯度: >96.00%

    WLSEAGPVVTVRALRGTGSW是一种心肌细胞特异性肽。

  • GC72191 structure
    GC72191Pep19-2.5
    CAS: 1322711-38-5
    纯度: >98.00%

    Pep19-2.5是一种合成的抗毒素肽,阻断细胞内内毒素信号级联。

  • GC72216 structure
    GC72216(Gly14)-Humanin (human) (acetate)
    纯度: >98.00%

    (Gly14)-Humanin (human) (acetate)是Humanin的类似物,其中第14个氨基酸丝氨酸被甘氨酸(Gly)取代。

  • GC72251 structure
    GC72251Tripeptide-32
    CAS: 1185583-20-3
    纯度: >99.00%

    Tripeptide-32是一种具有抗衰老作用的生物活性肽,已被报道用作化妆品成分。

  • GC72318 structure
    GC72318Tulisokibart
    CAS: 2648504-55-4
    纯度: 95.00%

    Tulisokibart (PRA023)是一种人源化IgG1-κ单克隆抗体,靶向TNFSF15/TL1A。

  • GC72319 structure
    GC72319Atrosab
    CAS: 1365659-05-7
    纯度: >96.00%

    Atrosab是一种人源化IgG1拮抗性抗TNFR1抗体。

  • GC72337 structure
    GC72337Anti-Mouse 4-1BB/CD137 Antibody (3H3)
    纯度: >99.00%

    Anti-Mouse 4-1BB/CD137 Antibody (3H3)是来源于宿主大鼠的抗小鼠4-1BB IgG2a抗体抑制剂。

  • GC72359 structure
    GC72359Quilizumab
    CAS: 1228538-47-3
    纯度: >96.00%

    Quilizumab(抗人NGcGM3重组抗体)是一种人源化IgG1κ单克隆抗体。

  • GC72360 structure
    GC72360Ruplizumab
    CAS: 220651-94-5
    纯度: >99.00%

    Ruplizumab(BG 9588)是一种人源化单克隆抗CD40L(TNF受体)IgG1κ抗体。

  • GC72364 structure
    GC72364Toralizumab
    CAS: 252662-47-8
    纯度: 95.00%

    Toralizumab(IDEC-131)是一种针对CD40L(CD154)的人源化单克隆抗体(mAb),由人γ1重链和人κ轻链组成。

  • GC72365 structure
    GC72365Visilizumab
    CAS: 219716-33-3
    纯度: >98.00%

    Visilizumab(抗人CD3E重组抗体)是一种人源化低Fc受体结合的抗CD3单克隆IgG2抗体。

  • GC72378 structure
    GC72378Neihulizumab
    CAS: 2158362-38-8
    纯度: >98.00%

    Neihulizumab(ALTB-168)是一种免疫检查点激动性抗体,与人CD162(PSGL-1)结合,导致活化T细胞下调。

  • GC72386 structure
    GC72386Afelimomab
    CAS: 156227-98-4
    纯度: >99.00%

    Afelimomab(MAK 195F)是一种抗肿瘤坏死因子F(ab')2单克隆抗体片段。

  • GC72419 structure
    GC72419Iscalimab
    CAS: 2031153-61-2
    纯度: >99.00%

    Iscalimab(CFZ-533)是一种靶向CD40的非耗竭性IGg1单克隆抗体(KD:0.3nM)。

  • GC72423 structure
    GC72423Letolizumab
    CAS: 1450981-87-9
    纯度: 95.00%

    Letolizumab (BMS-986004)是一种靶向CD40L的单克隆抗体,其产生是为了表达缺乏效应功能的突变体IgG1,包括Fc结合和补体固定。

  • GC72440 structure
    GC72440Ozoralizumab
    CAS: 1167985-17-2
    纯度: >99.00%

    Ozoralizumab (ATN-103)是一种抗tnf α人源化抗体。

  • GC72463 structure
    GC72463Rulonilimab
    CAS: 2417124-95-7
    纯度: 95.00%

    Rulonilimab是一种针对PD-1的人IgG1单克隆抗体,其靶向、结合并抑制PD-1及其下游信号通路。

  • GC72511 structure
    GC72511L-Cystathionine dihydrochloride
    CAS: 61125-50-6
    纯度: >99.50%

    L-Cystathionine dihydrochloride是一种非蛋白硫醚,是与含硫氨基酸代谢状态相关的关键氨基酸。

  • GC72575 structure
    GC72575L-Glutamic acid monosodium (hydrate)
    CAS: 6106-04-3
    纯度: >98.00%

    L-Glutamic acid monosodium (hydrate)是一种营养添加剂和调味剂。